Antiangiogenic effects of marine sponge derived compounds on cancer

Environmental Toxicology and Pharmacology

Volumn 36, Issue 3, 2013, Pages 1097-1108

  Senthilkumar, Kalimuthu ^a   Venkatesan, Jayachandran ^a   Manivasagan, Panchanathan ^a   Kim, Se Kwon ^a  

^a Pukyong National University   (South Korea)

Author keywords

Alkaloids; Anti angiogenesis; Cancer; Metastasis; Polyketide; Sponge

Indexed keywords

AEROPLYSININ 1; ANGIOGENIN; ANGIOSTATIN; BASTADIN 6; CORTIOSTATIN A; EPIDERMAL GROWTH FACTOR; ERIBULIN; FIBROBLAST GROWTH FACTOR 2; GLOBOSTELLATIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; MOTUPORAMINE C; MYCOTHIAZOLE 1; NATURAL PRODUCT; PLACENTAL GROWTH FACTOR; SMENOSPONGINE; SPONGISTATIN 1; SUBERREAMOLINE A; THROMBOCYTE FACTOR 4; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG POTENCY; ENDOMETRIUM CANCER; ENDOTHELIUM CELL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KAPOSI SARCOMA; LUNG CANCER; MALIGNANT MESOTHELIOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SPONGE (PORIFERA); STOMACH CANCER; UTERINE CERVIX CARCINOMA;

ALKALOIDS; ANTI-ANGIOGENESIS; CANCER; METASTASIS; POLYKETIDE; SPONGE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PORIFERA; PROGNOSIS; REGIONAL BLOOD FLOW;

EID: 84886005261     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2013.09.014     Document Type: Review

References (92)

1. Achen M.G., Jeltsch M., Kukk E., Mäkinen T., Vitali A., Wilks A.F., Alitalo K., Stacker S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. 1998, 95:548-553.
2. Amioka T., Kitadai Y., Tanaka S., Haruma K., Yoshihara M., Yasui W., Chayama K. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur. J. Cancer 2002, 38:1413-1419.
3. Aoki S., Cho S.H., Ono M., Kuwano T., Nakao S., Kuwano M., Nakagawa S., Gao J.Q., Mayumi T., Shibuya M. Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells. Anticancer Drugs 2006, 17:269-278.
4. Aoki S., Watanabe Y., Sanagawa M., Setiawan A., Kotoku N., Kobayashi M. Cortistatins A, B, C, and D, anti-angiogenic steroidal alkaloids, from the marine sponge Corticium simplex. J. Am. Chem. Soc. 2006, 128:3148-3149.
5. Aoki S., Watanabe Y., Tanabe D., Arai M., Suna H., Miyamoto K., Tsujibo H., Tsujikawa K., Yamamoto H., Kobayashi M. Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids. Bioorg. Med. Chem. 2007, 15:6758-6762.
6. Bai Y.J., Huang L.Z., Zhou A.Y., Zhao M., Yu W.Z., Li X.X. Antiangiogenesis effects of endostatin in retinal neovascularization. J. Ocul. Pharmacol. Ther. 2013, 29:619-626.
7. Baldwin M.E., Catimel B., Nice E.C., Roufail S., et al. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. J. Biol. Chem. 2001, 276:19166-19171.
8. Bellomo D., Headrick J.P., Silins G.U., et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 2000, 86:29-35.
9. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
10. Blunt J.W., Copp B.R., Munro M.H., Northcote P.T., Prinsep M.R. Marine natural products. Nat. Prod. Rep. 2011, 28:196-268.
11. Bottaro D.P., Liotta L.A. Cancer: out of air is not out of action. Nat. Index 2003, 423:593-595.
12. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003, 9:653-660.
13. Cigler T., Vahdat L.T. Eribulin mesylate for the treatment of breast cancer. Expert Opin. Pharmacother. 2010, 11:1587-1593.
14. Claesson-Welsh L., Welsh M., Ito N., et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. 1998, 95:5579-5583.
15. Cobleigh M.A., Langmuir V.K., Sledge G.W., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 2003, 30:117-124.
16. Coultas L., Chawengsaksophak K., Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005, 438:937-945.
17. Cox M.C., Dahut W.L., Figg W.D. The use of thalidomide in androgen-independent prostate cancer. Urol. Oncol. 2006, 24:246.
18. Evans D.B. Preoperative chemoradiation for pancreatic cancer. Semin. Oncol. 2005, 32:25-29.
19. Faulkner D.J. Marine natural products. Nat. Prod. Rep. 2001, 18:1-49.
20. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc. Med. 1993, 3:244-250.
21. Ferrara N., Mass R.D., Campa C., Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 2007, 58:491-504.
22. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Nat. Cancer Ins. 1990, 82:4-7.
23. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-30.
24. Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 1971, 133:275-288.
25. Furudoi A., Tanaka S., Haruma K., et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 2002, 62:157-166.
26. Goldberg R.M. Advances in the treatment of metastatic colorectal cancer. Oncologist 2005, 10:40-48.
27. Gunningham S.P., Currie M.J., Han, et al. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin. Cancer Res. 2000, 6:4278-4286.
28. Hashimoto I., Kodama J., Seki N., Hongo A., Yoshinouchi M., Okuda H., Kudo T. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Brit. J. Cancer 2001, 85:93.
29. Hirai M., Nakagawara A., Oosaki T., Hayashi Y., Hirono M., Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol. Oncol. 2001, 80:181-188.
30. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Eng. J. Med. 2004, 350:2335-2342.
31. Joukov V., Kumar V., Sorsa T., Arighi E., Weich H., Saksela O., Alitalo K. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J. Biol. Chem. 1998, 273:6599-6602.
32. Jussila L., Valtola R., Partanen T.A., Salven P., et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998, 58:1599-1604.
33. Kajita T., Ohta Y., Kimura K., et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Brit. J. Cancer 2001, 85:255-260.
34. Kirsch M., Strasser J., Allende R., Bello L., Zhang J., Black P.M. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. 1998, 58:4654-4659.
35. Klagsbrun M., Moses M.A. Molecular angiogenesis. Chem. Biol. 1999, 6:217-224.
36. Kong D., Yamori T., Kobayashi M., Duan H. Antiproliferative and antiangiogenic activities of smenospongine, a marine sponge sesquiterpene aminoquinone. Marine Drugs 2011, 9:154-161.
37. Kotoku N., Tamada N., Hayashi A., Kobayashi M. Synthesis of BC-ring model of globostellatic acid X methyl ester, an anti-angiogenic substance from marine sponge. Bioorg. Med. Chem. Lett. 2008, 18:3532-3535.
38. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 2006, 24:401-406.
39. Lee S.W., Jeong H.K., Lee J.Y., et al. Hypoxic priming of mESCs accelerates vascular lineage differentiation through HIF1-mediated inverse regulation of Oct4 and VEGF. EMBO Mol. Med. 2012, 4:924-938.
40. Leung T.W., Xue W.C., Cheung A.N., Khoo U.S., Ngan H. Proliferation to apoptosis ratio as a prognostic marker in adenocarcinoma of uterine cervix. Gynecol. Oncol. 2004, 92:866-872.
41. Long H.J. Current research directions for locally advanced cervix cancer. Curr. Oncol. Rep. 2003, 5:468-472.
42. Lucas R., Holmgren L., Garcia I., et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998, 92:4730-4741.
43. Lyttle D.J., Fraser K.M., Fleming S.B., Mercer A.A., Robinson A.J. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 1994, 68:84-92.
44. Ma J., Pulfer S., Li S., Chu J., Reed K., Gallo J.M. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001, 61:5491-5498.
45. Maisonpierre P.C., Suri C., Jones P.F., Papadopoulos N., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
46. Majima M., Hayashi I., Muramatsu M., Katada J., Yamashina S., Katori M. Cyclooxygenase -2 enhances basic fibroblast growth factor induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Brit. J. Pharmacol. 2009, 130:641-649.
47. Martínez-Poveda B., Rodríguez-Nieto S., García-Caballero M., Medina M.Á., Quesada A.R. The antiangiogenic compound aeroplysinin-1 induces apoptosis in endothelial cells by activating the mitochondrial pathway. Marine Drugs 2012, 10:2033-2046.
48. Mathieu V., Wauthoz N., Lefranc F., et al. Cyclic versus hemi-bastadins. pleiotropic anti-cancer effects: from apoptosis to anti-angiogenic and anti-migratory effects. Molecules 2013, 18:3543-3561.
49. Mojzis J., Varinska L., Mojzisova G., Kostova I., Mirossay L. Antiangiogenic effects of flavonoids and chalcones. Pharmacol. Res. 2008, 57:259-265.
50. Morgan J.B., Mahdi F., Liu Y., Coothankandaswamy V., Jekabsons M.B., Johnson T.A., Sashidhara K.V., Crews P., Nagle D.G., Zhou Y.D. The marine sponge metabolite mycothiazole: a novel prototype mitochondrial complex I inhibitor. Bioorg. Med. Chem. 2010, 18:5988-5994.
51. Mylona E., Alexandrou P., Mpakali A., et al. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and-D and VEGF receptor 3 in invasive breast carcinoma. Eur. J. Surg. Oncol. 2007, 33:294-300.
52. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 2000, 18:1135.
53. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70:461-477.
54. Nishida N., Yano H., Komai K., Nishida T., Kamura T., Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004, 101:1364-1374.
55. Nishida N., Yano H., Nishida T., Kamura T., Kojiro M. Angiogenesis in cancer. Vasc. Health Risk Manage. 2006, 2:213-219.
56. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
57. O-charoenrat P., Rhys-Evans P., Archer D., Eccles S. C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol. 2002, 38:73-80.
58. Ogawa S., Oku A., Sawano A., Yamaguchi S., Yazaki Y., Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 1998, 273:31273-31282.
59. Ohta Y., Shridhar V., Bright R., et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Brit. J. Cancer 1999, 81:54.
60. Olofsson B., Pajusola K., Kaipainen A., et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. 1996, 93:2576-2581.
61. Olsson A.K., Johansson I., Åkerud H., Einarsson B., Christofferson R., Sasaki T., Timpl R., Claesson-Welsh L. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res. 2004, 64:9012-9017.
62. Pan L., Baek S., Edmonds P.R., et al. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Rad. Oncol. 2013, 8:100.
63. Pawlik J.R., McFall G., Zea S. Does the odor from sponges of the genus Ircinia protect them from fish predators?. J. Chem. Ecol. 2002, 28:1103-1115.
64. Rafii S., Skobe M. Splitting vessels: keeping lymph apart from blood. Nat. Med. 2003, 9:166-168.
65. Rehn M., Veikkola T., Kukk-Valdre E., et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. 2001, 98:1024-1102.
66. Richelle-Maurer E., Gomez R., Braekman J.C., et al. Primary cultures from the marine sponge Xestospongia muta (Petrosiidae, Haplosclerida). J. Biotechnol. 2003, 100:169-176.
67. Rodríguez-Nieto S., González-Iriarte M., Carmona R., et al. Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. FASEB J. 2002, 16:261-263.
68. Roskelley C.D., Williams D.E., McHardy L.M., Leong K.G., Troussard A., Karsan A., Andersen R.J., Dedhar S., Roberge M. Inhibition of tumor cell invasion and angiogenesis by motuporamines. Cancer Res. 2001, 61:6788-6794.
69. Rothmeier A.S., Ischenko I., Joore J., et al. Investigation of the marine compound spongistatin 1 links the inhibition of PKCα translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J. 2009, 23:1127-1137.
70. Salven P., Lymboussaki A., Heikkilä P., et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am. J. Pathol. 1998, 153:103.
71. Sashidhara K.V., White K.N., Crews P. A selective account of effective paradigms and significant outcomes in the discovery of inspirational marine natural products. J. Nat. Prod. 2009, 72:588-603.
72. Sato Y., Kamiyama H., Usui T., Saito T., Osada H., Kuwahara S., Kiyota H. Synthesis and anti-angiogenic activity of cortistatin analogs. Biosci. Biotechnol. Biochem. 2008, 72:2992-2997.
73. Schyschka L., Rudy A., Jeremias I., et al. Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP. Leukemia 2008, 22:1737-1745.
74. Semenza G.L. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 2002, 64:993-998.
75. Shaala L.A., Youssef D.T., Sulaiman M., et al. Subereamolline A as a potent breast cancer migration, invasion and proliferation inhibitor and bioactive dibrominated alkaloids from the red sea sponge Pseudoceratina arabica. Marine Drugs 2012, 10:2492-2508.
76. Sipkema D., Franssen M.C., Osinga R., Tramper J., Wijffels R.H. Marine sponges as pharmacy. Mar. Biotechnol. 2005, 7:142-162.
77. Skobe M., Hawighorst T., Jackson D.G., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7:192-198.
78. Sonnenschein R.N., Johnson T.A., Tenney K., Valeriote F.A., Crews P. A reassignment of (-) mycothiazole and the isolation of a related diol. J. Nat. Prod. 2006, 69:145-147.
79. Stack M.S., Gately S., Bafetti L.M., Enghild J.J., Soff G.A. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem. J. 1999, 340:77.
80. Stalmans I., Ng Y.S., Rohan R., et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 2002, 109:327-336.
81. Talagas M., Uguen A., Garlantezec R., Fournier G., Doucet L., Gobin E., Marcorelles P., Volant A., De Braekeleer M. VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer. Anticancer Res. 2013, 33:2065-2075.
82. Teicher B.A. A systems approach to cancer therapy. Cancer Metast. Rev. 1996, 15:247-272.
83. Thomas T., Rusch D., DeMaere M.Z., et al. Functional genomic signatures of sponge bacteria reveal unique and shared features of symbiosis. ISME J. 2010, 4:1557-1567.
84. Tournaire R., Simon M.P., Le Noble F., Eichmann A., England P., Pouysségur J. A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep. 2004, 5:262-267.
85. Wang T.B., Chen Z.G., Wei X.Q., Wei B., Dong W.G. Serum vascular endothelial growth factor C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer. ANZ J. Surg. 2011, 81:694-699.
86. Wickström S.A., Alitalo K., Keski-Oja J. Endostatin associates with integrin α5β1 and caveolin-1 and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res. 2002, 62:5580-5589.
87. Wu H.C., Huang C.T., Chang D.K. Anti-angiogenic therapeutic drugs for treatment of human cancer. J. Cancer Mol. 2008, 4:37-45.
88. Xu H., Zhang T., Man G.C.W., et al. Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis 2013, 1-11.
89. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Eng. J. Med. 2003, 349:427-434.
90. Yokoyama Y., Charnock-Jones D., Licence D., et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Brit. J. Cancer 2003, 88:237-244.
91. Yonekura H., Sakurai S., Liu X., Migita H., et al. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. J. Biol. Chem. 1999, 274:35172-35178.
92. Zhao G., Yan W., Chen E., Yu X., Cai W. Numerical simulation of the inhibitory effect of angiostatin on metastatic tumor angiogenesis and microenvironment. Bull. Mathemat. Biol. 2013, 75:274-287.